Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CATHY ENG and VAN KARLYLE MORRIS.
CATHY ENG
Connection Strength
6.225
VAN KARLYLE MORRIS
  1. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023 01 20; 41(3):678-700.
    View in: PubMed
    Score: 0.901
  2. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res. 2017 11; 15(11):1542-1550.
    View in: PubMed
    Score: 0.629
  3. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
    View in: PubMed
    Score: 0.609
  4. Metastatic Anal Cancer and Novel Agents. Surg Oncol Clin N Am. 2017 01; 26(1):133-142.
    View in: PubMed
    Score: 0.603
  5. Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. J Gastrointest Oncol. 2016 Oct; 7(5):721-726.
    View in: PubMed
    Score: 0.593
  6. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2015 Nov; 20(11):1247-52.
    View in: PubMed
    Score: 0.551
  7. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel). 2023 Mar 10; 15(6).
    View in: PubMed
    Score: 0.231
  8. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. Curr Treat Options Oncol. 2022 08; 23(8):1073-1085.
    View in: PubMed
    Score: 0.220
  9. Anal Cancer: Emerging Standards in a Rare Disease. J Clin Oncol. 2022 08 20; 40(24):2774-2788.
    View in: PubMed
    Score: 0.219
  10. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656.
    View in: PubMed
    Score: 0.217
  11. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.
    View in: PubMed
    Score: 0.204
  12. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020 Apr 14; 11(15):1334-1343.
    View in: PubMed
    Score: 0.189
  13. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.158
  14. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8.
    View in: PubMed
    Score: 0.131
  15. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014.
    View in: PubMed
    Score: 0.127
  16. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.127
  17. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.055
  18. Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):974-984.
    View in: PubMed
    Score: 0.055
  19. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
    View in: PubMed
    Score: 0.054
  20. Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiother Oncol. 2020 10; 151:56-57.
    View in: PubMed
    Score: 0.048
  21. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770.
    View in: PubMed
    Score: 0.048
  22. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199.
    View in: PubMed
    Score: 0.048
  23. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.048
  24. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.045
  25. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.040
  26. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.039
  27. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.